Navigation Links
March of Dimes Awards $250,000 Prize to Scientists Who Explained Human Sex Chromosomes
Date:5/2/2011

DENVER, May 2, 2011 /PRNewswire-USNewswire/ -- Two scientists who pioneered research on the X and Y chromosomes have been chosen to receive the 2011 March of Dimes Prize in Developmental Biology.

Patricia Ann Jacobs, OBE, DSc, FRS, professor of Human Genetics, Southampton University Medical School and co-director of Research, Wessex Regional Genetics Laboratory, Salisbury, England and David C. Page, MD, director, Whitehead Institute, investigator of the Howard Hughes Medical Institute and professor of Biology at Massachusetts Institute of Technology, Cambridge, will share this year's prize.

Patricia Ann Jacobs was the first to describe a human sex chromosome abnormality with her landmark 1959 paper on Klinefelter syndrome, a disorder involving an additional X chromosome. 

David Page's studies of the Y chromosome revealed its role as a complex genetic system with many specialized functions, far beyond determining male sex.

"Taken together, the research  of Patricia Ann Jacobs and David Page has expanded medicine's ability to diagnose and understand the basis of infertility and many other diseases," said Michael Katz, MD, senior vice president for Research and Global Programs at the March of Dimes.

The prize was presented today to Patricia Ann Jacobs and David Page at a gala black-tie dinner and ceremony held at the Four Seasons Hotel, here. They also delivered the Sixteenth Annual March of Dimes Prize Lecture at the Colorado Convention Center at the annual meeting of the Pediatric Academic Societies. CBS sportscaster Greg Gumbel, member of the March of Dimes national Honorary Board of Trustees, hosted the award ceremony.

Individuals who receive the March of Dimes Prize are leaders in the field of developmental biology. Their pioneering research offers hope for prevention and treatments for some of the most serious birth defects and other human diseases.

The March of Dimes Prize in Developmental Biology has been awarded annually since 1996 to investigators whose research has profoundly advanced the science that underlies the understanding of birth defects. The March of Dimes Foundation created the Prize as a tribute to Dr. Jonas Salk shortly before his death in 1995. Dr. Salk received Foundation support for his work to create a polio vaccine. The prize is a cash award of $250,000 and a silver medal in the design of the Roosevelt dime, in honor of President Franklin D. Roosevelt, who founded the March of Dimes.

In its 16-year history, the March of Dimes Prize in Developmental Biology has been the crowning glory of a distinguished research career or a stepping stone on the path toward future honors for researchers. In fact, five past March of Dimes Prize recipients have gone on to win a Nobel Prize®. 

The March of Dimes is the leading nonprofit organization for pregnancy and baby health.  With chapters nationwide and its premier event, March for Babies®, the March of Dimes works to improve the health of babies by preventing birth defects, premature birth and infant mortality. For the latest resources and information, visit marchofdimes.com or nacersano.org.

The March for Babies is sponsored nationally by Kmart, Farmers Insurance Group, Bayer HealthCare, CIGNA, United Airlines, Famous Footwear, FedEx, Sanofi Pasteur, First Response, and Mission Pharmacal. To join an event near you, visit marchforbabies.org.


'/>"/>
SOURCE March of Dimes
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion To Host Conference Call To Provide a Business Update and Report Fourth Quarter 2010 Financial Results on March 25, 2011
2. PharmAthene to Host Year-End 2010 Earnings Conference Call and Webcast on Monday, March 28, 2011
3. TPI Attends 23rd ROTH Annual OC Growth Stock Conference from March 13-16, 2011
4. Reminder Webcast Alert: Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2010 Financial Results on March 11, 2011
6. Transgenomic to Hold Fourth Quarter Financial Results Conference Call on March 11, 2011
7. NeoStem to Present at Cowen Group 31st Annual Health Care Conference on March 7 and 8
8. ShangPharma Corp. to Announce Fourth Quarter and Full Year 2010 Financial Results on March 15, 2011
9. UT Arlington Honors Collaborative Research During March 4 Engineering Research Building Dedication
10. Progenitor Cell Therapy to Present at 6th Annual New York Stem Cell Summit on Tuesday, March 1
11. NeoStem to Present at Wall Street Forum 2011 Financial Conference on Tuesday, March 1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... 2017 , ... Total Orthopedics and Sports Medicine ( http://www.totalorthosportsmed.com ... operation took place on Wednesday, January 11, 2017 at Long Island Jewish, Valley ... discectomy and fusion on a 42 year old female who was in a ...
(Date:1/18/2017)... FL (PRWEB) , ... January 18, 2017 , ... ... weakness and paralysis, today announced that it has submitted a 510(k) to the ... bikes that utilize MYOLYN’s patent-pending functional electrical stimulation (FES) technology. , The ...
(Date:1/18/2017)... ... January 18, 2017 , ... BidMed, LLC, announced it will ... genetic testing lab equipment from two different leading institutes. This highly specialized laboratory equipment ... the United States. This 1-day online auction will take place on BidMed’s website ...
(Date:1/18/2017)... 18, 2017 Shareholder rights law firm Johnson ... the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... with the proposed sale of the Company to Eli ... develops small molecules for the acute treatment of migraines. ... had signed a definitive merger agreement with Eli Lilly. ...
Breaking Biology Technology:
(Date:1/3/2017)... LAS VEGAS , Jan. 3, 2017 ... announced the introduction of Onitor Track, an innovative biometric ... and men, showcasing this month at the 2017 Consumer ... . In the U.S., the World ... affect more than two-thirds of adults who are overweight ...
(Date:12/19/2016)... y TORONTO , 19 de diciembre de 2016 ... Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo humanizado ... tipos de tumor en 2017, con múltiples sitios previstos a lo ... ... objetivo en el factor inhibidor de leucemia (LIF), una citoquina pleiotrópica ...
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
Breaking Biology News(10 mins):